Successful IND Submission in 4 Weeks with 70% Compliance Cost Savings

A global top 20, Pharma company, involved in developing a set of diagnostic and monitoring tools for Celiac disease, approached Freyr for Investigational New Drug (IND) submissions. Apart from criticality of IND submissions, clients’ strategy for trials in two more regions and requirements of eCTD conversions made the project more challenging.

Read this case study to get insights on how Freyr successfully completed compliant IND submissions in just 4 weeks and met timelines for Phase 1 trials.

Download

Location

903/50 Clarence St,
Sydney NSW 2000,
(9th level of building 50),
Australia

Quick Inquiry
x